1. Home
  2. NXL vs KALA Comparison

NXL vs KALA Comparison

Compare NXL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXL
  • KALA
  • Stock Information
  • Founded
  • NXL 2010
  • KALA 2009
  • Country
  • NXL United States
  • KALA United States
  • Employees
  • NXL N/A
  • KALA N/A
  • Industry
  • NXL Medical Specialities
  • KALA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXL Health Care
  • KALA Health Care
  • Exchange
  • NXL Nasdaq
  • KALA Nasdaq
  • Market Cap
  • NXL 24.2M
  • KALA 26.2M
  • IPO Year
  • NXL 2022
  • KALA 2017
  • Fundamental
  • Price
  • NXL $1.19
  • KALA $3.72
  • Analyst Decision
  • NXL Strong Buy
  • KALA Strong Buy
  • Analyst Count
  • NXL 1
  • KALA 2
  • Target Price
  • NXL $5.00
  • KALA $13.50
  • AVG Volume (30 Days)
  • NXL 126.6K
  • KALA 56.4K
  • Earning Date
  • NXL 05-13-2025
  • KALA 05-14-2025
  • Dividend Yield
  • NXL N/A
  • KALA N/A
  • EPS Growth
  • NXL N/A
  • KALA N/A
  • EPS
  • NXL N/A
  • KALA N/A
  • Revenue
  • NXL $131,065.00
  • KALA N/A
  • Revenue This Year
  • NXL $79.59
  • KALA N/A
  • Revenue Next Year
  • NXL $334.65
  • KALA N/A
  • P/E Ratio
  • NXL N/A
  • KALA N/A
  • Revenue Growth
  • NXL N/A
  • KALA N/A
  • 52 Week Low
  • NXL $0.53
  • KALA $2.92
  • 52 Week High
  • NXL $4.49
  • KALA $11.20
  • Technical
  • Relative Strength Index (RSI)
  • NXL 30.13
  • KALA 46.95
  • Support Level
  • NXL $1.18
  • KALA $3.67
  • Resistance Level
  • NXL $1.24
  • KALA $4.16
  • Average True Range (ATR)
  • NXL 0.07
  • KALA 0.31
  • MACD
  • NXL 0.02
  • KALA 0.08
  • Stochastic Oscillator
  • NXL 18.18
  • KALA 53.89

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: